MD-18

Asset

Disrupts Nck1 binding to specifically inhibit PTP-1B activity and improve insulin sensitivity.

Stage: Phase 1
Modality: Peptide
Target: Insulin/IGF-1 signalling; 2
Indications: 0
Trials: 1
Developer

Indications

2

Obesity
Phase 1, doi.org, 5 Jun 2026
Type 2 diabetes
Phase 1, doi.org, 5 Jun 2026

In the full profile

Targets and what it contains2
Owner and partners1
Evidence for its targets3
Competitors12
Aging relevance1
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.